Pfenex Inc., a clinical stage biotech company based in San Diego, California, has announced execution of an agreement with Hospira Inc. (Illinois) to exclusively develop… Read More »Lucentis biosimilar advances through collaboration between Pfenex Inc. and Hospira Inc.
Research, published in the New England Journal of Medicine (NEJM), has concluded that aflibercept is more effective than bevacizumab and ranibizumab at improving vision for… Read More »NEJM research recommends use of aflibercept (Eylea) as first-line therapy in patients with a VA of 20/50 or worse
Publication of the 2014 US Surgeon General’s Report entitled, “The Health Consequences of Smoking – 50 Years of Progress”, has concluded the existence of a… Read More »US Surgeon General’s report concludes a causal relationship exists between cigarette smoking and age-related macular degeneration (AMD)
A research team from the Hebrew University of Jerusalem recently demonstrated that the same part of the visual cortex activated in sighted individuals when reading… Read More »Congenitally blind patients reading “through sound” show activation of visual cortex in the brain including response to colour.
Spark Therapeutics, Inc. (NASDAQ: ONCE) has initiated enrolment of a Phase I/II gene therapy study in choroideremia (CHM), an X-linked retinopathy, manifesting as night-blindness in… Read More »Spark Therapeutics initiates enrolment of Phase I/II study for choroideremia gene therapy treatment
Research published in the journal Translational Vision Science & Technology (TVST, 2014, Vol. 3, No. 6,Article 5) reports that a first-in-man study of a “posterior… Read More »Novel micro-pump device for sustained delivery of anti-VEGF treatments completes first-in-man safety study
Research conducted at the University of Kiel, Germany, and funded by Novartis AG (SIX: NOVN; NYSE: NVS), suggests that aflibercept, marketed by Regeneron (NASDAQ: REGN)… Read More »Aflibercept may impair wound healing in in vitro cell studies according to Novartis sponsored research
Spark Therapeutics, Inc., (ONCE, NASDAQ), Philadelphia, PA, a retinal gene therapy company, made an impressive IPO debut on the NASDAQ, Friday, January 30th. The company… Read More »Spark Therapeutics makes 117% gain in first day of trading on NASDAQ
Researchers based at the Cantonal Hospital of Lucerne, Switzerland have published research findings suggesting a modest superiority of aflibercept (2 mg) and ranibizumab (0.5 mg)… Read More »Swiss study concludes a modest clinical superiority of aflibercept (2 mg) and ranibizumab (0.5 mg) over other anti-VEGF formulations and dosages
Researchers from the University of Brescia, Italy have published research findings suggesting that smartphones, in combination with an external lens device, can accurately detect retinal… Read More »Comparison of smartphone ophthalmoscopy with slit-lamp biomicroscopy shows potential in grading of diabetic retinopathy